YAP Triggers Bladder Cancer Proliferation by Affecting the MAPK Pathway

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Dec 4

PMID 33273857

Citations 12

Authors

Dandan Qiu

Yan Zhu

Zhicheng Cong

Affiliations

Soon will be listed here.

Abstract

Background: The transcriptional regulator YAP is frequently overexpressed in human cancers, such as breast and pancreatic cancers, plays an important role in tumorigenesis and can regulate many factors affecting cancer progression. These observations encouraged us to investigate the effect of YAP expression on bladder cancer.

Methods: The changes in multiple cellular functions associated with tumor progression including cell proliferation, cell migration, cell cycle, and cell apoptosis were assessed after YAP knockdown/overexpression in bladder cancer cell lines. Additionally, Western blot was developed to verify the change of proteins caused by YAP knockdown/overexpression.

Results: YAP had relatively higher expression in bladder cancer tissues than in normal tissues. The proliferation and migration of bladder cancer cells were inhibited by YAP knockdown but were promoted by its overexpression. This promoting effect was accompanied by the increased activity of MAPK/ERK pathway.

Conclusion: Our data established that YAP is an oncogene involved in bladder cancer and thus can be a potential target for treatment.

Citing Articles

Advances in research on the carcinogenic mechanisms and therapeutic potential of YAP1 in bladder cancer (Review).

Huang T, Fan L, Tang J, Chen S, Du G, Zhang N Oncol Rep. 2024; 53(1).

PMID: 39540392 PMC: 11599795. DOI: 10.3892/or.2024.8843.

Mechanism and application of feedback loops formed by mechanotransduction and histone modifications.

Sun H, Gao Y, Ma X, Deng Y, Bi L, Li L Genes Dis. 2024; 11(5):101061.

PMID: 39071110 PMC: 11282412. DOI: 10.1016/j.gendis.2023.06.030.

The Antimicrobial Peptide Tilapia Piscidin 4 Induced the Apoptosis of Bladder Cancer Through ERK/SIRT1/PGC-1α Signaling Pathway.

Chang C, Chang P, Lee Y, Pan C, Chang H, Wu W Probiotics Antimicrob Proteins. 2024; .

PMID: 38805142 DOI: 10.1007/s12602-024-10296-2.

DeepKEGG: a multi-omics data integration framework with biological insights for cancer recurrence prediction and biomarker discovery.

Lan W, Liao H, Chen Q, Zhu L, Pan Y, Chen Y Brief Bioinform. 2024; 25(3).

PMID: 38678587 PMC: 11056029. DOI: 10.1093/bib/bbae185.

MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.

Zhenhai Z, Qi C, Shuchao Z, Zhongqi W, Xue S, Zhijun G BMC Cancer. 2023; 23(1):956.

PMID: 37814205 PMC: 10563299. DOI: 10.1186/s12885-023-11175-9.

References

Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P . Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett. 2019; 469:310-322. DOI: 10.1016/j.canlet.2019.11.001. View

Wu Y, Zheng Q, Li Y, Wang G, Gao S, Zhang X . Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res. 2019; 38(1):376. PMC: 6712726. DOI: 10.1186/s13046-019-1346-1. View

Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon V . YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int. 2019; 19:179. PMC: 6626386. DOI: 10.1186/s12935-019-0898-7. View

Han H, Qi R, Zhou J, Ta A, Yang B, Nakaoka H . Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction. Mol Cell. 2018; 72(2):328-340.e8. PMC: 6195446. DOI: 10.1016/j.molcel.2018.08.038. View

Yang C, Stampouloglou E, Kingston N, Zhang L, Monti S, Varelas X . Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. EMBO Rep. 2018; 19(6). PMC: 5989844. DOI: 10.15252/embr.201643577. View

Dong L, Lin F, Wu W, Liu Y, Huang W . Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 2018; 15(6):645-652. PMC: 5930467. DOI: 10.7150/ijms.23460. View

Elster D, Tollot M, Schlegelmilch K, Ori A, Rosenwald A, Sahai E . TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. Nat Commun. 2018; 9(1):3115. PMC: 6079100. DOI: 10.1038/s41467-018-05370-7. View

Noguchi S, Saito A, Nagase T . YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer. Int J Mol Sci. 2018; 19(11). PMC: 6274979. DOI: 10.3390/ijms19113674. View

Hua X, Xu J, Deng X, Xu J, Li J, Zhu D . New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer. Cancer Lett. 2018; 436:38-51. PMC: 6245652. DOI: 10.1016/j.canlet.2018.08.013. View

10.

Zhang Z, Du J, Wang S, Shao L, Jin K, Li F . OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Mol Cell. 2018; 73(1):7-21.e7. DOI: 10.1016/j.molcel.2018.10.030. View

11.

Deng Y, Lu J, Li W, Wu A, Zhang X, Tong W . Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation. Nat Commun. 2018; 9(1):4564. PMC: 6212432. DOI: 10.1038/s41467-018-07022-2. View

12.

Chen D, Sun Y, Wei Y, Zhang P, Rezaeian A, Teruya-Feldstein J . LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012; 18(10):1511-7. PMC: 3684419. DOI: 10.1038/nm.2940. View

13.

Yoo W, Lee J, Jun E, Noh K, Lee S, Jung D . The YAP1-NMU Axis Is Associated with Pancreatic Cancer Progression and Poor Outcome: Identification of a Novel Diagnostic Biomarker and Therapeutic Target. Cancers (Basel). 2019; 11(10). PMC: 6826421. DOI: 10.3390/cancers11101477. View

14.

Zhao T, Jiang W, Wang X, Wang H, Zheng C, Li Y . ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. Cancer Res. 2016; 77(4):874-885. PMC: 5313376. DOI: 10.1158/0008-5472.CAN-16-2170. View

15.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

16.

Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L . YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2015; 35(12):1541-53. PMC: 4695331. DOI: 10.1038/onc.2015.219. View

17.

Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins R, Chaudhry S . Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013; 15(6):637-46. PMC: 3836234. DOI: 10.1038/ncb2756. View

18.

Rausch V, Bostrom J, Park J, Bravo I, Feng Y, Hay D . The Hippo Pathway Regulates Caveolae Expression and Mediates Flow Response via Caveolae. Curr Biol. 2019; 29(2):242-255.e6. PMC: 6345631. DOI: 10.1016/j.cub.2018.11.066. View

19.

Chen W, Wang H, Liu Y, Xu W, Ling C, Li Y . Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells. J Cell Biochem. 2019; 121(1):632-641. DOI: 10.1002/jcb.29308. View

20.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View